

Special Issue

T and B Cell Responses to HIV and Tuberculosis Infections/Coinfection and Vaccinations

Message from the Guest Editor

Given the equal importance of T and B cell immunity in HIV/Mtb infections, coinfection, and vaccinations, the following aspects are of interest in this Special Issue:

- Characterization of T and B cell immunity after HIV and/or Mtb infections and coinfection using human cohorts.
- Develop vaccines for HIV/Mtb single infections or coinfection and test their efficacy in appropriate animal models.
- Characterizing T and B cell epitopes and testing their potential for vaccine development.
- Identify novel T cell subsets or new functions of existing T cell subsets during HIV/Mtb infections and coinfection.
- Profiling of TCR/BCR after infections or vaccinations using high-throughput T/B cell receptor sequencing technology.
- Exploration of novel techniques to characterize T and B cell immune responses to HIV/Mtb infections.

Guest Editor

Dr. Guohua Yi

Center for Biomedical Research, University of Texas Health Center at Tyler, Tyler, TX, USA

Deadline for manuscript submissions

31 December 2025



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/213335

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).